Scientific posters


  1. Rizzieri et al. CLAVELA, a Randomised Phase III Study of Elacytarabine (CP-4055) vs. Investigator's Choice in Patients with Late Stage Acute Myeloid leukemia (AML). American Society of Clinical Oncology (ASCO) 2011. Abstract #83258
  2. Rizzieri et al. A Phase II Study of Elacytarabine (CP-4055) plus Idarubicin as Second Course Remission-Induction Therapy in Patients with Acute Myeloid Leukaemia. American Society of Clinical Oncology (ASCO) 2011. Abstract #83277
  3. Brueckner et al. Modulation of cellular uptake and increased therapeutic efficacy of the azacytidine-elaidic acid ester CP-4200 in vitro and in vivo. American Association for Cancer Research (AACR) 2011. Abstract #2013
  4. Stuurman et al. Phase I study of oral CP-4126 in patients with advanced solid tumours. EORTC Berlin 2010
  5. O'Brien S. et al.: A Phase II Multicentre Study with Elacytarabine as Second Salvage Therapy in Patients with AML. ASH 2009. Abstract #17724
  6. O'Brien, S. et al.: A Phase I study with CP-4055 and idarubicin in patients with refractory/relapsed AML. European Hematology Association (EHA) 2009. Abstract #1485
  7. Giles, F. et al.: A phase II study with elacytarabine in patients with second salvage AML. American Society of Clinical Oncology (ASCO) 2009. Abstract #7047
  8. Nilsson, B. et al.: First in-human study of a novel nucleoside analogue, Intravenous CP-4126, in patients with advanced solid tumours. American Society of Clinical Oncology (ASCO) 2009. Abstract #2577
  9. O'Brien, S. et al.:  A Phase I dose finding study with elacytarabine (CP-4055) plus idarubicin in patients with relapsed/refractory AML (AACR) 2009. Abstract #4589
  10. O'Brien, S. et al.: A Phase I/IIStudy with CP-4055 in Patients with Hematologic Malignancies. American Society of Hematology (ASH) 2008. Abstract #949
  11. O'Brien, S. et al.: Plasma Pharmacokinetics of CP-4055 in Patients with Acute Myeloid Leukaemia at the Recommended Phase II Dose. EORCTC-NCI-AAfCR, 2008. Poster #471
  12. Aamdal, S. et al.: First-in-man study of a novel nucleoside analogue, CP-4126, in patients with advanced solid tumours. European Society for Medical Oncology (ESMO), 2008. Poster #496P. 
  13. Dueland, S. et al.: A multicentre, dose-finding, phase II Study of CP-4055 in combination with sorafenib in patients with metastatic malignant melanoma. European Society for Medical Oncology (ESMO), 2008. Poster #790P. 
  14. O'Brien S.M. et al.: A Phase I study with CP-4055 in patients with hematologic malignancies, American Society of Clinical Oncology (ASCO), 2008. Abstract #2532.
  15. Adema A.D. et al.: Fatty acid derivatives of cytarabine and gemcitabine, CP-4055 and CP-4126, show  prolonged cellular retention compared to the parent drug. American Association for Cancer Research (AACR) 2008. Abstract #5740
  16. Aamdal, S. et al.: A phase I study of novel nucleoside analogue, CP-4126, in patients with advanced solid tumours. European CanCer Organisation (ECCO) 2007. Abstract #725.
  17. Giles, F.J. et al.: A Phase I study with CP-4055 in patients with hematologic malignancies. American Society of Hematology (ASH) 2007. Abstract #901.
  18. Giles, F.J. et al.: CP-4055 in patients with haematologic malignancies - A Phase I study. European Hematology Association (EHA), 2007. Abstract #1199. 
  19. Giles, F.J. et al.: CP-4055 in patients with haematologic malignancies - A Phase I study. Proceedings of American Association for Cancer Research (AACR) 2007. Abstract #3185.
  20. Bruheim et al.: Antitumor activity of CP-4055 is enhanced in combination with bevacizumab, cetuximab and trastuzumab in human NSCLC xenografts..  AACR-EORTC-NCI 2007. B278[1]
  21. Adams, D.J. et al.: Antiproliferative Activity of ELACYTTM (CP-4055) in Combination with Cloretazine (VPN40101M), Idarubicin or Gemcitabine in HL-60 Human Myeloid Leukemia Cells. Amercian Society of Hematology (ASH) 2006. Abstract #1991.
  22. Adema, A.D. et al.: The fatty acid derivatives of Ara-C, CP-4055, and gemcitabine, CP-4126, enhance the cytotoxic effect of oxaliplatin and Docetaxel. Proceedings of the American Association for Cancer Research (AACR) 2006. Abstract #2119.
  23. Bergman, A.M. et al.: Oral antitumour effect and in vitro antiproliferative activity of CP-4126 a fatty acid derivative of gemcitabine in cell lines and human cancer xenograft models. Proceedings of the American Association for Cancer Research (AACR), Vol 46, 2005. Abstract #1444.
  24. Aamdal S. et al.: ELACYTTM (CP-4055), a novel cytotoxic agent, shows favourable safety and efficacy clinical results in the first phase study. (Abstract #1482) European CanCer Conference (ECCO), 2005.
  25. Raymond, E. et al.: ELACYTTM (CP-4055), a novel cytotoxic agent, administered according to three intermittent weekly or biweekly schedules to patients with advanced or metastatic solid tumours; phase I preliminary results. European CanCer Conference (ECCO) 2005. Abstract #1483.
  26. Aamdal, S. et al.: Favourable phase I clinical results and pharmacokinetic (PK) data with the novel Lipid Vector Technology-cytotoxic agent, CP-4055. American Association for Cancer Research (AACR) 2005. Abstract #3976.
  27. Raymond, E. et al.: Phase I trial of CP-4055, a novel cytotoxic agent, given according to three intermittent weekly or biweekly schedules in patients with advanced or metastatic solid tumours: preliminary results. American Association for Cancer Research (AACR) 2005. Abstract #473.
  28. Raymond, E. et al.: Pharmacokinetics of CP-4055 a novel cytotoxic agent, in two phase I trials using a daily 5 days schedule and three intermittent weekly or biweekly schedules. American Association for Cancer Research (AACR) 2005. Abstract #3975.
  29. Delaunoit, T. et al.: A three schedule Phase I trial of CP-4055 (ELACYTTM), weekly and every two weeks in patients with advanced or metastatic solid tumors. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement), 2004: 2049
  30. Aamdal, S. et al.: Phase I trial of a nucleoside analogue CP-4055 given daily for 5 days every 3 weeks in patients with advanced solid tumours. American Society of Clinical Oncology (ASCO) 2004. Abstract #2049.
  31. Leusink-Muis, A. et al.: P-4112 and P-4114, derivatives of betamethasone and methylprednisolone, respectively, are more potent in reducing rat peritoneal cell numbers and activity.  Oral presentation at the XVI World Congress of Asthma, Buenos Aires, Argentina, 1999.
  32. Peters, G.J. et al.: Cell specific cytotoxicity and structure-activity relationship (SAR) of lipophilic 1-b-D-arabinofuranosylcytosine (cytarabine) derivatives.  Poster 104, XIII International Round Table "Nucleosides, Nucleotides and their biological applicationFs", Montpellier, France, 1998.